CDK4/6抑制剂在HR+/HER-2−乳腺癌中耐药机制及生物标志物研究进展Research Progress on Resistance Mechanism and Biomarker of CDK4/6 Inhibitor in HR+/HER-2− Breast Cancer
袁晓莉, 王振波
临床医学进展Vol.11 No.12, 全文下载: PDF HTML XML DOI:10.12677/ACM.2021.1112851, December 16 2021
EGFR-TKIs耐药与EGFR突变非小细胞肺癌中PD-L1表达的研究进展Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer
温雅婷, 高俊珍
临床医学进展Vol.14 No.1, 全文下载: PDF HTML XML DOI:10.12677/ACM.2024.141027, January 8 2024
肺癌EGFR-TKI联合贝伐珠单抗治疗进展Progress of EGFR-TKI Combined with Bevacizumab in the Treatment of Lung Cancer
谢志丹, 梁亚奇, 徐芹芹 国家自然科学基金支持
临床医学进展Vol.12 No.3, 全文下载: PDF HTML XML DOI:10.12677/ACM.2022.123258, March 16 2022
晚期肺腺癌患者获得性EGFR-TKI耐药后治疗的研究进展Research Progress of Acquired EGFR-TKI Resistance in Patients with Advanced Lung Adenocarcinoma
王 康, 胡雪婷, 罗 虎, 周向东 科研立项经费支持
临床医学进展Vol.11 No.9, 全文下载: PDF HTML XML DOI:10.12677/ACM.2021.119578, September 10 2021
新型PHD抑制剂类口服抗贫血药物分子的计算机辅助设计Computer Aided Design of New PHD Inhibitors for Oral Anti-Anemia Drug Molecules
杨汉跃, 董淑波, 陈学民
药物化学Vol.5 No.2, 全文下载: PDF HTML XML DOI:10.12677/HJMCe.2017.52003, May 24 2017
EGFR T790M位点突变型非小细胞肺癌耐药机制及耐药后的综合治疗EGFR T790M Site-Mutated Non-Small Cell Lung Cancer Drug Resistance Mechanism and Comprehensive Treatment after Drug Resistance
武卉淇, 马金华
临床医学进展Vol.12 No.7, 全文下载: PDF HTML XML DOI:10.12677/ACM.2022.127991, July 22 2022